Locus Biosciences

OverviewSuggest Edit

Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA. Locus Biosciences designs and creates novel CRISPR RNAs and uses a powerful CRISPR-Cas system, referred to as Cascade/Cas3, that kills target bacteria by irreversibly destroying the bacterial DNA. The irreversible destruction of DNA is the primary differentiator between Cas3 and Cas9, as Cas9 makes double-stranded breaks that can be repaired by the cell. The Locus Biosciences platform enables the design and development of powerful antimicrobials that avoid currently known antibiotic resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical disease areas ranging from resistant bacterial infections to the microbiome.
TypePrivate
Founded2015
HQRaleigh, US
Websitelocus-bio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Sep 2019)42(-2%)

Locus Biosciences Office Locations

Locus Biosciences has an office in Raleigh
Raleigh, US (HQ)
Raleigh, NC, USA
Show all (1)

Locus Biosciences Financials and Metrics

Summary Metrics

Founding Date

2015

Locus Biosciences total Funding

$19 m

Locus Biosciences latest funding size

$19 m

Time since last funding

2 years ago

Locus Biosciences investors

Locus Biosciences's latest funding round in November 2017 was reported to be $19 m. In total, Locus Biosciences has raised $19 m
Show all financial metrics

Locus Biosciences Online and Social Media Presence

Embed Graph

Locus Biosciences News and Updates

Locus Biosciences fetches $19 mln Series A

https://www.prnewswire.com/news-releases/locus-biosciences-closes-19-million-series-a-led-by-artis-ventures-for-crispr-cas3-antimicrobials-300555115.html

Locus Biosciences Blogs

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications Research Triangle Park, NC, and Union City, CA; July 17, 2018 – Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision …

Locus Biosciences Frequently Asked Questions

  • When was Locus Biosciences founded?

    Locus Biosciences was founded in 2015.

  • How many employees does Locus Biosciences have?

    Locus Biosciences has 42 employees.

  • Who are Locus Biosciences competitors?

    Competitors of Locus Biosciences include Spring Bank Pharmaceuticals, TCR2 Therapeutics and MetaboGen AB.

  • Where is Locus Biosciences headquarters?

    Locus Biosciences headquarters is located at Raleigh, NC, USA, Raleigh.

  • Where are Locus Biosciences offices?

    Locus Biosciences has an office in Raleigh.

  • How many offices does Locus Biosciences have?

    Locus Biosciences has 1 office.